|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl J Med2012，366，26： | 1 |
| 2 | Improved survival with ipilimumab in patients with metastatic melanoma 显示文摘 | Hodi FS O'Day SJ McDermott DF | 2010 | N Engl J Med2010，363，8： | 1 |
| 3 | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl J Med2012，366，26： | 1 |
| 4 | Safety,activity, and immune con'elates of Anti-PD-I antibody in cancer显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl J Med2012，366，26： | 1 |
| 5 | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer 显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl J Med2012，366，26： | 1 |
| 6 | Improved survival with ipilimumab in patients with metastatic melanoma显示文摘 | Hodi FS O'day SJ Mcdermott DF | 2010 | N Engl J Med2010，363，8： | 1 |
| 7 | Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocytemacrophage colony-stimulating fator by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma 显示文摘 | Soiffer R Hodi FS Haluska F | 2003 | J Clin Oncol2003，21，： | 1 |
| 8 | Safety,activity,and immunecorrelates of anti-PD-1 antibody in cancer显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | Engl J Med2012，366，26： | 1 |
| 9 | Improved survival with ipilimumab in patients with metastatic mel-anoma显示文摘 | Hodi FS O' Day S J McDermott DF | 2010 | N Engl J Med2010，363，8： | 1 |
| 10 | Improved survival with ipilimumab in pa- tients with metastatic melanoma 显示文摘 | Hodi FS O'Day SJ McDermott DF | 2010 | N Engl J Med2010，363，8： | 1 |
| 11 | Improved survival with ipilimumab in patients with metastatic melanoma显示文摘 | Hodi FS O'Day SJ McDermott DF | | 0，，8： | 1 |
| 12 | Combined nivolumab and ipilimumab or monotherapy in untreated melanoma 显示文摘 | Larkin J Hodi FS Wolchok JD | 2015 | N Engl Med2015，373，13： | 1 |
| 13 | Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patient 显示文摘 | Hodi FS Butler M Oble DA | 2008 | Proc Natl Acad Sci U S A2008，105，8： | 1 |
| 14 | Imatinib for melanomas harboring mutationally activated or amplified kit arising on mucosal,acral,andchronically sun-damaged skin显示文摘 | Hodi FS Corless CI Giobbie-Hurder A | 2013 | J Clin Oncol2013，31，26： | 1 |
| 15 | KIT gene mutations and copy number in melanoma subtypes显示文摘 | Beadling C Jacobson-Dunlop E Hodi FS | | 0，，21： | 1 |
| 16 | Programmed death-ligand 1 and programmed death--1 inhibiting molecular pathways: next generation immunotherapy显示文摘 | Ghen DS Irving BA Hodi FS | 2012 | Glin Gancer Res2012，18，24： | 1 |
| 17 | Safety, activity, and immune correlates of Anti-PD-1 antibody in cancer显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl J Med2012，366，26： | 1 |
| 18 | Improved survival with ipilimumab in patients with metastatic melanoma 显示文摘 | Hodi FS O'Day SJ McDermott DF | 2010 | N Engl J Med2010，363，8： | 1 |
| 19 | A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stageⅢ or stage IV melanoma显示文摘 | Hodi FS Friedlander PA Atkins MB | 2011 | J Clin Oneol2011，29，： | 1 |
| 20 | Major response to imatinib mesylate in KIT-mutated melanoma显示文摘 | Hodi FS Friedlander P Corless CL | | 0，，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员